51 studies found for:    parkinson's disease AND baylor
Show Display Options
Rank Status Study
21 Completed
Has Results
Phase I Deep Brain Stimulation (DBS) vs. Best Medical Therapy (BMT) Trial
Condition: Parkinson's Disease
Interventions: Device: Bilateral Deep Brain Stimulation;   Other: best medical therapy
22 Completed
Has Results
Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
Condition: Idiopathic Parkinson's Disease
Interventions: Genetic: CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]);   Procedure: Sham Surgery
23 Completed
Has Results
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
Condition: Parkinson's Disease
Interventions: Drug: Carbidopa/levodopa/entacapone;   Drug: Immediate release carbidopa/levodopa
24 Completed A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).
Condition: Parkinson's Disease
Interventions: Drug: IPX066;   Drug: regular carbidopa-levodopa
25 Terminated NET-PD LS-1 Creatine in Parkinson's Disease
Condition: Parkinson's Disease
Interventions: Drug: creatine;   Other: placebo
26 Terminated Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease
Condition: Early Parkinson Disease
Intervention: Drug: aplindore MR tablets or Placebo
27 Recruiting National Parkinson Foundation Quality Improvement Initiative
Condition: Parkinson's Disease
Intervention:
28 Completed A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
Condition: Parkinson's Disease With Cognitive Impairments
Interventions: Drug: safinamide;   Drug: placebo
29 Completed
Has Results
Phase II Subthalamic Nucleus (STN) vs. Globus Pallidus (GPi) Trial
Condition: Parkinson's Disease
Intervention: Device: Bilateral Deep Brain Stimulation
30 Completed Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations
Condition: Parkinson's Disease
Interventions: Drug: rasagiline mesylate;   Drug: 1.0 mg rasagiline mesylate;   Other: Placebo
31 Completed MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
Condition: Idiopathic Parkinson's Disease
Intervention: Drug: Safinamide (as add-on therapy)
32 Completed A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa
Condition: Parkinson's Disease
Intervention: Drug: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)
33 Completed Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study)
Condition: Parkinson Disease
Intervention:
34 Terminated
Has Results
Effects of Coenzyme Q10 (CoQ) in Parkinson Disease
Condition: Parkinson Disease
Interventions: Drug: Coenzyme Q10 with vitamin E;   Drug: placebo with vitamin E
35 Terminated Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease
Condition: Parkinson Disease
Interventions: Drug: CEP-1347 10mg;   Drug: CEP1347 25mg;   Drug: CEP-1347 50mg;   Other: Placebo Comparator
36 Completed
Has Results
Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment
Condition: Parkinson's Disease
Interventions: Drug: Tigan®;   Drug: Placebo
37 Active, not recruiting A Trial of Levodopa in Angelman Syndrome
Condition: Angelman Syndrome
Intervention: Drug: Levodopa/carbidopa
38 Completed
Has Results
A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa
Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH);   Non-diabetic Neuropathy;   Primary Autonomic Failure;   Dopamine Beta Hydroxylase Deficiency
Interventions: Drug: Placebo;   Drug: Droxidopa
39 Completed Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
Condition: Progressive Supranuclear Palsy
Interventions: Drug: Davunetide;   Drug: Placebo
40 Completed A Study of ACR16 for the Treatment of Patients With Huntington's Disease
Condition: Huntington Disease
Interventions: Drug: ACR16 10 mg;   Drug: ACR16 22.5 mg;   Drug: ACR16 45 mg;   Other: Placebo

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-51) Show next page of results
Indicates status has not been verified in more than two years